Table 2. TEA trial: GPs’ mean baseline prescription (in the 3 months preceding the outreach visit) of drugs considered in the primary outcomes, expressed as DDD per 1000 patients.

Drugs considered	Group 1: information on drugs for the treatmentof benign prostatic hyperplasia	Group 2: information on drugsfor the treatment of osteoporosis
finasteride	5.35	5.46
dutasteride	4.09	4.30
alfuzosin	9.98	9.66
terazosin	4.64	4.73
tamsulosin	11.05	11.11
alendronate	7.35	7.29
risedronate	3.01	2.98